Annexon Inc (ANNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annexon Inc (ANNX) has a cash flow conversion efficiency ratio of -0.229x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.80 Million) by net assets ($204.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check ANNX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annexon Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Annexon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See ANNX net assets for net asset value and shareholders' equity analysis.
Annexon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dazzle Fashion Co Ltd
SHG:603587
|
0.031x |
|
Hefei Kewell Power System Co Ltd
SHG:688551
|
0.001x |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
0.057x |
|
CNB Financial Corporation
NASDAQ:CCNE
|
0.008x |
|
Xiamen XGMA Machinery Co Ltd
SHG:600815
|
0.358x |
|
Central Reinsurance Corp
TW:2851
|
0.050x |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
0.037x |
|
Minerals 260 Ltd
AU:MI6
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Annexon Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Annexon Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Annexon Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $211.65 Million | $-186.36 Million | -0.880x | -118.70% |
| 2024-12-31 | $293.11 Million | $-118.01 Million | -0.403x | +16.73% |
| 2023-12-31 | $250.56 Million | $-121.14 Million | -0.483x | +3.89% |
| 2022-12-31 | $231.19 Million | $-116.31 Million | -0.503x | -9.95% |
| 2021-12-31 | $231.91 Million | $-106.11 Million | -0.458x | -196.73% |
| 2020-12-31 | $344.28 Million | $-53.09 Million | -0.154x | +76.33% |
| 2019-12-31 | $43.53 Million | $-28.36 Million | -0.651x | -43.56% |
| 2018-12-31 | $37.88 Million | $-17.19 Million | -0.454x | -208.88% |
| 2017-12-31 | $-46.21 Million | $-19.26 Million | 0.417x | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more